BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein JS, Merdan S, Flowers CR, Koff JL. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert Rev Hematol 2019;12:959-73. [PMID: 31513757 DOI: 10.1080/17474086.2019.1660159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Jelicic J, Larsen TS, Frederiksen H, Andjelic B, Maksimovic M, Bukumiric Z. Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models - A Systematic Review. Clin Epidemiol 2020;12:537-55. [PMID: 32581596 DOI: 10.2147/CLEP.S244294] [Reference Citation Analysis]
2 Weng J, Chen L, Liu H, Yang X, Huang L. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma. Inflammation. [DOI: 10.1007/s10753-021-01609-6] [Reference Citation Analysis]
3 Jiang C, Teng Y, Zheng Z, Zhou Z, Xu J. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients. Quant Imaging Med Surg 2021;11:2509-20. [PMID: 34079720 DOI: 10.21037/qims-20-1166] [Reference Citation Analysis]
4 Sorigue M, Cañamero E, Sancho JM. Precision medicine in follicular lymphoma: Focus on predictive biomarkers. Hematol Oncol 2020;38:625-39. [PMID: 32700331 DOI: 10.1002/hon.2781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]